Article
HIV-1 vaccine immunogen design strategies
23 Jan 2015
Abstract excerpt
An effective human immunodeficiency virus type 1 (HIV-1) vaccine is expected to have the greatest impact on HIV-1 spread and remains a global scientific priority. Only one candidate vaccine has significantly reduced HIV-1 acquisition, yet at a limited efficacy of 31%, and none have delayed disease progression in vaccinated individuals. Thus, the challenge remains to develop HIV-1 immunogens that will elicit...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
